Insmed Inc. sell klostergang
Start price
05.09.17
/
50%
€23.52
Target price
29.12.17
€16.24
Performance (%)
20.60%
End price
29.12.17
€28.36
Summary
This prediction ended on 29.12.17 with a price of €28.36. The prediction closed with a disappointing performance of 20.60%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | -9.974% | -9.974% | 30.381% | 351.319% |
| iShares Core DAX® | -2,20 % | 0,67 % | 0,55 % | 51,11 % |
| iShares Nasdaq 100 | -2,63 % | 2,99 % | 34,11 % | 91,99 % |
| iShares Nikkei 225® | -2,02 % | 3,14 % | 53,42 % | 65,85 % |
| iShares S&P 500 | -1,67 % | 2,40 % | 23,22 % | 66,64 % |
Comments by klostergang for this prediction
In the thread Insmed Inc. diskutieren
klostergang stimmt der Sell-Einschätzung von kyron7htx zu
The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.
(Vom Mitglied beendet)